Clinical Trial

Efficacy and Safety of Sequential Autologous Hematopoietic Stem Cell Transplantation Combined With Tafasitamab, Lenalidomide, and Standard Immunochemotherapy for Relapsed/Refractory Diffuse Large B-cell Lymphoma

Active, Not Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This study aims to evaluate the efficacy and safety of tafasitamab combined with lenalidomide plus standard immunochemotherapy, followed by sequential autologous stem cell transplantation (ASCT), in patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL).
Trial Details
NCT Number NCT07621406
Lead Sponsor The First Affiliated Hospital of Soochow University
Conditions Relapsed/Refractory Diffuse Large B Cell Lymphoma
Enrollment 25 participants
Start Date 2026-01-01
Primary Completion 2028-12-31 (estimated)
Study Completion 2028-12-31 (estimated)
Updated on ClinicalTrials.gov 2026-06-02